Journal of Isfahan Medical School

Journal of Isfahan Medical School

Efficacy and Side-Effects of Megestrol Acetate Tablets on Postpone Menstruation Compared with Low-Dose Estrogen Combined Oral Contraceptives (LD)

Document Type : Original Article (s)

Authors
Tajossadat Allameh 1
Zahra Allameh 1
Fatemeh Moatamedy 2
1 Associate Professor, Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Student of Medicine, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Women's menstrual suppression is desired for many reasons. Menstrual suppresion, especially during the holidays, trips, camps, military exercises, special events, academic examinations or athletic events is desirable. This study, with emphasis on safety of megestrol acetate tablets, aimed to determine the effect of this tablet on retardation of menstruation compared with low-dose estrogen combined oral contraceptives (LD).Methods: In this clinical-trial study, 140 applicants to postpone menstruation left for pilgrimage randomly devided to two groups, LD and megestrol acetate recipients. Data were collected through a researcher-made questionnaire and were analyzed by Mann-Whitney Uand chi-square tests.Findings: The frequency of individuals reported symptoms such as headache or dizziness (P < 0.05), nausea or vomiting (P < 0.05), changes in appetite (P < 0.05) and changes in sexual desire (P < 0.05), was significantly more in the LD recipients compared with megestrol acetates.Conclusion: Megestrol acetate can be seen as a drug with the same efficacy of LD, but safer than it, to postpone the menstruation.
Keywords
Postpone menstruation
Low-dose estrogen combined oral contraceptives (LD)
Megestrol acetate
  1. Estanislau do Amaral MC, Hardy E, Hebling EM, Faundes A. Menstruation and amenorrhea: opinion of Brazilian women. Contraception 2005; 72(2): 157-61.
  2. Kaunitz AM, Barbieri RL, Falk SJ. Hormonal contraception for suppression of menstruation [Online] 2009. Available from: URL: http://www.uptodate.com/contents/hormonal-contraception-for-suppression-of-menstruation.
  3. Gold MA, Duffy K. Extended cycling or continuous use of hormonal contraceptives for female adolescents. Curr Opin Obstet Gynecol 2009; 21(5): 407-11.
  4. Thurlimann B, Castiglione M, Hsu-Schmitz SF, Cavalli F, Bonnefoi H, Fey MF, et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK). Eur J Cancer 1997; 33(7): 1017-24.
  5. Kropsky B, Shi Y, Cherniack EP. Incidence of deep-venous thrombosis in nursing home residents using megestrol acetate. J Am Med Dir Assoc 2003; 4(5): 255-6.
  6. Koffel JC. Pills and minipills. Bull Soc Pharm Strasb 1978; 21(1): 43-53. [In French].
  7. Ghorashi Z, Taleghani F, Shafiee M. Failure and side effects of contraceptive pills used for postponement of menstrual bleeding in Hajj pilgrims of Kerman, 2000. J Shaheed Sadoughi Univ Med Sci 2005; 12(4): 65-70. [In Persian].
  8. Owens J. New option for reversible suppression of menstruation. Drug Discov Today 2001; 6(19): 975-7.
  9. Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p. 914-7, 922-4.
  10. Gibbs RS, KarlanBY, Haney AF, Nygaard IE. Danforth's obstetrics and gynecology. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008. p. 571-2.
  11. Cunningham F, Leveno K, Bloom S, Hauth J, Rouse D, Spong C. Williams obstetrics. 23th ed. New York, NY: McGraw-Hill; 2009.
  12. Hovey D, Pruitt J, Ryde T. Nanoparticulate megestrol formulations [Patent No: US 20050233001 A1]. 2010.
  13. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17(10): 3299-306.
  14. Quint EH. Menstrual issues in adolescents with physical and developmental disabilities. Ann NY Acad Sci 2008; 1135: 230-6.
  15. Martin KA, Barbieri RL, Snyder PJ, Crowley WF. Overview of the use of estrogen-progestin contraceptives [Online] 2013. Available from: URL: http://www.uptodate.com/contents/overview-of-the-use-of-estrogen-progestin-contraceptives.
  16. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95(2): 261-6.
  17. Lowdermilk L, Perry SE. Maternity nursing. 6th ed. Philadelphia, PA: Mosby; 2003.
  18. Martin KA, Douglas P, Barbieri RL, Crowley WF. Risks and side effects associated with estrogen-progestin contraceptives [Online] 2009. Available from: URL: http://www.uptodate.com/contents/risks-and-side-effects-associated-with-estrogen-progestin-contraceptives.
Journal of Isfahan Medical School
Volume 31, Issue 234 - Serial Number 234
March and April 2013
Pages 532-543

  • Receive Date 22 May 2013
  • Accept Date 06 April 2022